These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23027880)

  • 1. EDSS variability before randomization may limit treatment discovery in primary progressive MS.
    Zhang J; Waubant E; Cutter G; Wolinsky JS; Glanzman R
    Mult Scler; 2013 May; 19(6):775-81. PubMed ID: 23027880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Composite end points to assess delay of disability progression by MS treatments.
    Zhang J; Waubant E; Cutter G; Wolinsky J; Leppert D
    Mult Scler; 2014 Oct; 20(11):1494-501. PubMed ID: 24675040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
    Zephir H; de Seze J; Duhamel A; Debouverie M; Hautecoeur P; Lebrun C; Malikova I; Pelletier J; Sénéchal O; Vermersch P
    J Neurol Sci; 2004 Mar; 218(1-2):73-7. PubMed ID: 14759636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
    Hawker K; O'Connor P; Freedman MS; Calabresi PA; Antel J; Simon J; Hauser S; Waubant E; Vollmer T; Panitch H; Zhang J; Chin P; Smith CH;
    Ann Neurol; 2009 Oct; 66(4):460-71. PubMed ID: 19847908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
    Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
    Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.
    Wang G; Cutter GR; Cofield SS; Lublin F; Wolinsky JS; Gustafson T; Krieger S; Salter A
    Mult Scler; 2017 Jun; 23(7):982-987. PubMed ID: 27682227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical scales in progressive MS: predicting long-term disability.
    Bosma LV; Kragt JJ; Knol DL; Polman CH; Uitdehaag BM
    Mult Scler; 2012 Mar; 18(3):345-50. PubMed ID: 21868487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lesion enhancement diminishes with time in primary progressive multiple sclerosis.
    Khaleeli Z; Ciccarelli O; Mizskiel K; Altmann D; Miller DH; Thompson AJ
    Mult Scler; 2010 Mar; 16(3):317-24. PubMed ID: 20203148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis.
    Laule C; Vavasour IM; Zhao Y; Traboulsee AL; Oger J; Vavasour JD; Mackay AL; Li DK
    Mult Scler; 2010 Jun; 16(6):670-7. PubMed ID: 20558500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
    Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis].
    Cadavid D; Tang Y; O'Neill G
    Rev Neurol; 2010 Sep; 51(6):321-9. PubMed ID: 20839168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
    Raghavan K; Healy BC; Carruthers RL; Chitnis T
    Mult Scler; 2015 Feb; 21(2):180-8. PubMed ID: 25070676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.